Background
Tissue Health Plus (THP) was established in 2023 as a wholly owned subsidiary of Sanara MedTech Inc., a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound, and skin markets. THP aimed to revolutionize the chronic wound care sector, a market valued at over $100 billion, by introducing value-based innovations. The company sought to address significant gaps in chronic wound care, where traditional approaches often yield healing rates between 40-66%, despite substantial annual expenditures.
Key Strategic Focus
THP's strategic focus was to develop and implement a value-based wound care model tailored for payers, risk-bearing entities, and value-based primary care companies. The company's objectives included:
- Standardizing Wound Care Protocols: Implementing consistent treatment protocols to enhance healing rates and reduce variability in care.
- Optimizing Revenue: Improving coding accuracy to ensure appropriate reimbursement and financial sustainability for healthcare providers.
- Reducing Administrative Burden: Streamlining administrative processes to allow healthcare providers to focus more on patient care.
- Facilitating Transition to Value-Based Care Models: Supporting healthcare providers in shifting from fee-for-service to value-based care models, aiming to improve patient outcomes and reduce costs.
The company utilized a technology platform that combined AI-powered clinical decision support, virtual care coordination, and an integrated provider network to deliver personalized precision wound care across various settings.
Financials and Funding
Specific details regarding THP's funding history, total funds raised, and notable investors are not publicly disclosed. However, in the second half of 2025, Sanara MedTech Inc. anticipated a total cash investment in THP ranging from $5.5 million to $6.5 million. The company did not expect material cash expenses related to THP after the end of 2025.
Pipeline Development
THP's primary initiative was the development and implementation of its value-based wound care platform. In July 2025, the company launched a pilot program in partnership with a wound care provider group delivering at-home care for chronic wounds across six states. This program aimed to validate and optimize THP's technology platform by providing real-world evidence of its effectiveness. The pilot program utilized THP's Co-Pilot software to standardize patient encounter planning and treatment interventions, ensuring compliance with reimbursement requirements. The company planned to expand the program to include additional practitioners and locations, with the goal of launching a pilot program with a payer during the second half of 2025.
Technological Platform and Innovation
THP's technological platform was designed to address critical gaps in chronic wound care through value-based innovation. Key features included:
- AI-Powered Clinical Decision Support: Utilizing artificial intelligence to assist healthcare providers in making informed clinical decisions, thereby improving patient outcomes.
- Virtual Care Coordination: Facilitating remote monitoring and management of chronic wounds, enhancing accessibility and efficiency of care.
- Integrated Provider Network: Connecting a network of healthcare providers to deliver coordinated and personalized wound care across various settings.
These technological innovations aimed to improve healing rates, reduce hospitalizations, and decrease the total cost of care for chronic wound patients.
Leadership Team
The leadership team of Tissue Health Plus included:
- Sam Muppalla: President and CEO of THP, leading the company's strategic initiatives and operations.
- Ron Nixon: Executive Chairman and CEO of Sanara MedTech Inc., overseeing the parent company's strategic direction and providing guidance to THP.
Specific details about other members of the leadership team are not publicly disclosed.
Leadership Changes
In September 2025, Sanara MedTech Inc. announced a planned CEO transition. Seth Yon, then serving as President and Chief Commercial Officer, was set to assume the role of President and Chief Executive Officer effective September 15, 2025. He was also to join the company's Board of Directors, succeeding Ron Nixon, who would continue as Executive Chairman.
Competitor Profile
The chronic wound care market is highly competitive, with several key players offering various solutions:
- Acelity L.P., Inc. (3M Company): Provides advanced wound care products and services.
- BSN Medical GmbH (Essity AB): Offers a range of wound care solutions.
- ConvaTec Group plc: Specializes in wound and skin care products.
- Integra LifeSciences Corporation: Provides regenerative technologies for wound care.
- Medtronic plc (Covidien plc): Offers a variety of wound care products.
- Mölnlycke Health Care: Provides wound care and surgical solutions.
- Organogenesis Holdings, Inc.: Specializes in regenerative medicine and wound care.
- Smith & Nephew plc: Offers advanced wound management products.
These competitors have established products and services in the wound care market, presenting challenges for THP in differentiating its value-based approach.
Strategic Collaborations and Partnerships
In April 2025, THP acquired CarePICS, a software application developer specializing in acute and post-acute wound care settings. This acquisition aimed to enhance THP's technological capabilities in wound care management.
Operational Insights
The decision to discontinue THP's operations was part of Sanara MedTech Inc.'s strategic realignment to improve operating efficiency and reallocate resources to its core surgical business. The winding down process was expected to continue through the end of 2025, with no material cash expenses related to THP anticipated after year-end.
Strategic Opportunities and Future Directions
Following the discontinuation of THP's operations, Sanara MedTech Inc. planned to focus on its core surgical business, which had demonstrated consistent net revenue growth over recent years. The company aimed to allocate capital toward opportunities with higher expected returns, leveraging its existing product portfolio and market presence to drive sustainable, long-term growth.
